CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.
You may also be interested in...
CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
CytRx, which has bet heavily on oncology since FDA put a hold on the CNS drug, plans to resume partnering talks for arimoclomol as it restarts the trial.
CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
CytRx, which has bet heavily on oncology since FDA put a hold on the CNS drug, plans to resume partnering talks for arimoclomol as it restarts the trial.
CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
CytRx's potentially disease-altering approach for neurological disorders got a new lease on life after FDA accepted a revised trial protocol and said the company could continue its Phase IIb trial in amyotrophic lateral sclerosis (Lou Gehrig's disease) patients, the firm announced Dec. 2